Indeed, the ABL kinase inhibitors imatinib, nilotinib, and GNF5, mainly used to treat leukemias, disrupt invadopodium precursor formation and cortactin phosphorylation-mediated invadopodium maturation, which leads to decreased actin polymerization, reduced ECM degradation, and impaired matrix-proteolysis dependent invasion of breast cancer cells. The gene discussed is CTTN; the disease is breast cancer.